Inflammatory Disease


Results from SOBI’S Pivotal Phase 2/3 Study of Emapalumab in Patients with Primary HLH Published in New England Journal of Medicine

SOBI announced that the results from the pivotal phase 2/3 study evaluating the efficacy and safety of emapalumab in patients with primary hemophagocytic lymphohistiocytosis (HLH) were published in the New England Journal of Medicine on 7 May 2020. Emapalumab is the...

Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for Phase 2 Trial of LYR-210 for Chronic Rhinosinusitis

Lyra Therapeutics announced the U.S. FDA has cleared the company’s Investigational New Drug (IND) application for LYR-210 for the treatment of chronic rhinosinusitis (CRS). Lyra plans to incorporate U.S. clinical sites into LANTERN, its ongoing global Phase 2 clinical...

Pin It on Pinterest